Literature DB >> 9799208

Association of a G994-->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese.

S Ichihara1, Y Yamada, M Yokota.   

Abstract

BACKGROUND: Although several genes or genetic loci that are responsible for or confer susceptibility to familial dilated cardiomyopathy (DCM) have been identified, genetic defects that underlie nonfamilial DCM remain to be characterized. Mice lacking manganese superoxide dismutase exhibit DCM, suggesting that impairment of the defense mechanisms against oxidative stress is an important susceptibility factor for DCM. Plasma platelet-activating factor (PAF) acetylhydrolase also acts as a key defense against oxidative stress by hydrolyzing PAF and oxidized phospholipids. Thus, abnormalities in the activity of this enzyme may result in predisposition to myocardial damage. METHODS AND
RESULTS: The possible association of a G994 (M allele)-->T (m allele) missense mutation in the plasma PAF acetylhydrolase gene with genetic susceptibility to nonfamilial DCM has now been investigated in 122 Japanese individuals with this condition and 226 healthy control subjects. PAF acetylhydrolase activity in plasma was significantly associated with plasma PAF acetylhydrolase genotype in both DCM patients and healthy control subjects. The frequency of the mutant m allele was significantly higher in DCM patients than in control subjects. Left ventricular mass (LVM) and the LVM index in DCM patients with Mm or mm genotypes were significantly greater than those in patients with the MM genotype.
CONCLUSIONS: The G994-->T mutation in the plasma PAF acetylhydrolase gene is associated with nonfamilial DCM in Japanese subjects. Although the mutation is unlikely to be a causative factor, it may contribute to genetic susceptibility to or progression of nonfamilial DCM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9799208     DOI: 10.1161/01.cir.98.18.1881

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Association between polymorphisms in the signal transducer and activator of transcription and dilated cardiomyopathy in the Chinese Han population.

Authors:  Ying Peng; Bin Zhou; Yanyun Wang; Yu Chen; Hui Li; Yaping Song; Lin Zhang; Li Rao
Journal:  Mol Cell Biochem       Date:  2011-09-23       Impact factor: 3.396

Review 2.  Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

Authors:  Giuseppe Maiolino; Valeria Bisogni; Giacomo Rossitto; Gian Paolo Rossi
Journal:  World J Cardiol       Date:  2015-10-26

Review 3.  The genomics of cardiovascular disorders: therapeutic implications.

Authors:  P Ferrari; G Bianchi
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 4.  The pathological roles of environmental and redox stresses in cardiovascular diseases.

Authors:  Sahoko Ichihara
Journal:  Environ Health Prev Med       Date:  2012-12-29       Impact factor: 3.674

5.  Lipoprotein-associated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis.

Authors:  Guo-Hua Zheng; Hai-Ying Chen; Shang-Quan Xiong; Jian-Feng Chu
Journal:  Mol Biol Rep       Date:  2010-11-24       Impact factor: 2.316

6.  Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults.

Authors:  Nels Olson; Ellen S O'Meara; Nancy S Jenny; Aaron R Folsom; Edwin G Bovill; Curt D Furberg; Susan R Heckbert; Bruce M Psaty; Mary Cushman
Journal:  Am J Hematol       Date:  2008-07       Impact factor: 10.047

Review 7.  Functional Consequences of Mutations and Polymorphisms in the Coding Region of the PAF Acetylhydrolase (PAF-AH) Gene.

Authors:  Diana M Stafforini
Journal:  Pharmaceuticals (Basel)       Date:  2009-11-20

8.  Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.

Authors:  Astrid Yeo; Li Li; Liling Warren; Jennifer Aponte; Dana Fraser; Karen King; Kelley Johansson; Allison Barnes; Colin MacPhee; Richard Davies; Stephanie Chissoe; Elizabeth Tarka; Michelle L O'Donoghue; Harvey D White; Lars Wallentin; Dawn Waterworth
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

9.  Functional polymorphism of the NFKB1 gene promoter is related to the risk of dilated cardiomyopathy.

Authors:  Bin Zhou; Li Rao; Ying Peng; Yanyun Wang; Yi Li; Linbo Gao; Yu Chen; Hui Xue; Yaping Song; Miao Liao; Lin Zhang
Journal:  BMC Med Genet       Date:  2009-05-31       Impact factor: 2.103

10.  Variants of resistin gene and the risk of idiopathic dilated cardiomyopathy in Pakistan.

Authors:  Sabir Hussain; Javeria Haroon; Shagufta Ejaz; Qamar Javed
Journal:  Meta Gene       Date:  2016-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.